{"id": 0, "relation": 0, "prompt": "<e1> Antacids </e1> : Absorption of a single dose of <e2> Myfortic </e2> was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.\n\n###\n\n", "completion": " false"}
{"id": 83, "relation": 1, "prompt": "Use of Anticoagulants and Antiplatelet Agents -- <e1> Streptase </e1> , Streptokinase, alone or in combination with antiplatelet agents and <e2> anticoagulants </e2> , may cause bleeding complications.\n\n###\n\n", "completion": " true"}
{"id": 10, "relation": 0, "prompt": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1> magnesium </e1> -aluminum containing <e2> antacids </e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.\n\n###\n\n", "completion": " false"}
{"id": 149, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : <e2> amantadine </e2> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 18, "relation": 0, "prompt": "Cyclosporine: When studied in stable renal transplant patients, <e1> cyclosporine </e1> , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e2> Myfortic </e2> .\n\n###\n\n", "completion": " false"}
{"id": 152, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e2> antihistamines </e2> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 24, "relation": 0, "prompt": "Both acyclovir/ <e1> ganciclovir </e1> and <e2> MPAG </e2> concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.\n\n###\n\n", "completion": " false"}
{"id": 156, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 26, "relation": 0, "prompt": "<e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that <e2> azathioprine </e2> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 160, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 27, "relation": 0, "prompt": "<e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and <e2> mycophenolate mofetil </e2> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 161, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 29, "relation": 0, "prompt": "<e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2> azathioprine </e2> or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 254, "relation": 1, "prompt": "<e1> Anticholinergics </e1> antagonize the effects of <e2> antiglaucoma agents </e2> .\n\n###\n\n", "completion": " true"}
{"id": 32, "relation": 0, "prompt": "Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that azathioprine and <e2> mycophenolate mofetil </e2> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 271, "relation": 1, "prompt": "<e1> Thiazide diuretics </e1> may accentuate the orthostatic hypotension that may occur with <e2> phenothiazines </e2> .\n\n###\n\n", "completion": " true"}
{"id": 38, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that <e1> azathioprine </e1> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2> azathioprine </e2> or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 296, "relation": 1, "prompt": "In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving <e1> methadone </e1> , treatment with <e2> PEG-Intron </e2> once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;\n\n###\n\n", "completion": " true"}
{"id": 40, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and <e1> mycophenolate mofetil </e1> inhibit purine metabolism, it is recommended that <e2> Myfortic </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 300, "relation": 1, "prompt": "Oral <e1> metronidazole </e1> has been reported to potentiate the anticoagulant effect of coumarin and <e2> warfarin </e2> , resulting in a prolongation of prothrombin time.\n\n###\n\n", "completion": " true"}
{"id": 51, "relation": 0, "prompt": "Therefore, do not administer <e1> Myfortic </e1> with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of <e2> Myfortic </e2> .\n\n###\n\n", "completion": " false"}
{"id": 306, "relation": 1, "prompt": "Concurrent use of <e1> alcohol </e1> and other CNS depression-producing drugs may increase the CNS depressant effects of <e2> methyprylon </e2> or these other medications.\n\n###\n\n", "completion": " true"}
{"id": 53, "relation": 0, "prompt": "Therefore, do not administer Myfortic with <e1> cholestyramine </e1> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of <e2> Myfortic </e2> .\n\n###\n\n", "completion": " false"}
{"id": 330, "relation": 1, "prompt": "- Cisapride, <e1> pimozide </e1> : Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2> macrolide antibacterials </e2> .\n\n###\n\n", "completion": " true"}
{"id": 55, "relation": 0, "prompt": "Oral <e1> Contraceptives </e1> : Given the different metabolism of <e2> Myfortic </e2> and oral contraceptives, no drug interaction between these two classes of drug is expected.\n\n###\n\n", "completion": " false"}
{"id": 637, "relation": 1, "prompt": "There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e1> proton pump inhibitors </e1> , including pantoprazole, and <e2> warfarin </e2> concomitantly.\n\n###\n\n", "completion": " true"}
{"id": 62, "relation": 0, "prompt": "Live Vaccines: During treatment with <e1> Myfortic </e1> , the use of <e2> live attenuated vaccines </e2> should be avoided and patients should be advised that vaccinations may be less effective.\n\n###\n\n", "completion": " false"}
{"id": 668, "relation": 1, "prompt": "Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as <e1> acetylsalicylic acid </e1> , dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2> TNKase </e2> therapy.\n\n###\n\n", "completion": " true"}
{"id": 74, "relation": 0, "prompt": "Use of <e1> Anticoagulants </e1> and Antiplatelet Agents -- Streptase, <e2> Streptokinase </e2> , alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.\n\n###\n\n", "completion": " false"}
{"id": 709, "relation": 1, "prompt": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and <e1> abciximab </e1> ) may increase the risk of bleeding if administered prior to or after <e2> Retavase </e2> therapy.\n\n###\n\n", "completion": " true"}
{"id": 80, "relation": 0, "prompt": "Use of Anticoagulants and <e1> Antiplatelet Agents </e1> -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and <e2> anticoagulants </e2> , may cause bleeding complications.\n\n###\n\n", "completion": " false"}
{"id": 835, "relation": 1, "prompt": "The CNS depressant effects of <e1> oxycodone hydrochloride </e1> may be additive with that of other <e2> CNS depressants </e2> ..\n\n###\n\n", "completion": " true"}
{"id": 87, "relation": 0, "prompt": "In the treatment of acute MI, <e1> aspirin </e1> , when not otherwise contraindicated, should be administered with <e2> Streptokinase </e2> ( see below ).\n\n###\n\n", "completion": " false"}
{"id": 836, "relation": 1, "prompt": "CYP3A4 Inhibitors: <e1> Ketoconazole </e1> , an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of <e2> tolterodine </e2> when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).\n\n###\n\n", "completion": " true"}
{"id": 92, "relation": 0, "prompt": "Usage with <e1> Alcohol </e1> : Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving <e2> pentazocine </e2> .\n\n###\n\n", "completion": " false"}
{"id": 1021, "relation": 1, "prompt": "Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , triamterene, amiloride) or potassium supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.\n\n###\n\n", "completion": " true"}
{"id": 101, "relation": 0, "prompt": "Although specific drug or food interactions with <e1> mifepristone </e1> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> mifepristone </e2> ).\n\n###\n\n", "completion": " false"}
{"id": 1041, "relation": 1, "prompt": "If a <e1> diuretic </e1> is also used, the risk of <e2> lithium </e2> toxicity may be increased.\n\n###\n\n", "completion": " true"}
{"id": 108, "relation": 0, "prompt": "Furthermore, <e1> rifampin </e1> , <e2> dexamethasone </e2> , St.\n\n###\n\n", "completion": " false"}
{"id": 1064, "relation": 1, "prompt": "<e1> Vasopressors </e1> , particularly metaraminol, may cause serious cardiac arrhythmias during <e2> halothane </e2> anesthesia and therefore should be used only with great caution or not at all.\n\n###\n\n", "completion": " true"}
{"id": 133, "relation": 0, "prompt": "<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>\n\n###\n\n", "completion": " false"}
{"id": 1079, "relation": 1, "prompt": "Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other <e2> CNS depressants </e2> such as alcohol, sedatives, antihistaminics, or psychotropic drugs.\n\n###\n\n", "completion": " true"}
{"id": 137, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1082, "relation": 1, "prompt": "Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other CNS depressants such as alcohol, sedatives, <e2> antihistaminics </e2> , or psychotropic drugs.\n\n###\n\n", "completion": " true"}
{"id": 170, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1083, "relation": 1, "prompt": "Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or <e2> psychotropic drugs </e2> .\n\n###\n\n", "completion": " true"}
{"id": 174, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1117, "relation": 1, "prompt": "The induction dose requirements of <e1> DIPRIVAN </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, <e2> morphine </e2> , meperidine, and fentanyl, etc.)\n\n###\n\n", "completion": " true"}
{"id": 175, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1118, "relation": 1, "prompt": "The induction dose requirements of <e1> DIPRIVAN </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, <e2> meperidine </e2> , and fentanyl, etc.)\n\n###\n\n", "completion": " true"}
{"id": 177, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), <e2> antihistamines </e2> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1734, "relation": 1, "prompt": "The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e1> neuromuscular blocking agents </e1> has been demonstrated in patients chronically administered phenytoin or <e2> carbamazepine </e2> .\n\n###\n\n", "completion": " true"}
{"id": 184, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1737, "relation": 1, "prompt": "While the effects of chronic <e1> phenytoin </e1> or carbamazepine therapy on the action of <e2> MIVACRON </e2> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.\n\n###\n\n", "completion": " true"}
{"id": 193, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1738, "relation": 1, "prompt": "While the effects of chronic phenytoin or <e1> carbamazepine </e1> therapy on the action of <e2> MIVACRON </e2> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.\n\n###\n\n", "completion": " true"}
{"id": 194, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1887, "relation": 1, "prompt": "The action of <e1> Mecamylamine </e1> may be potentiated by anesthesia, other antihypertensive drugs and <e2> alcohol </e2> .\n\n###\n\n", "completion": " true"}
{"id": 195, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1897, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably <e2> penicillin </e2> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 198, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1900, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e2> triiodothyronine </e2> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 202, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1901, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e2> phenytoin </e2> , sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 203, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1903, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 208, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1905, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 210, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1956, "relation": 1, "prompt": "<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e2> hypnotics </e2> , narcotic analgesics, sedatives, and tranquillisers.\n\n###\n\n", "completion": " true"}
{"id": 211, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1983, "relation": 1, "prompt": "The effects of <e1> anticholinergic drugs </e1> , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of <e2> triprolidine </e2> .\n\n###\n\n", "completion": " true"}
{"id": 214, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1986, "relation": 1, "prompt": "The effects of anticholinergic drugs, such as atropine and <e1> tricyclic antidepressants </e1> may be enhanced by the concomitant administration of <e2> triprolidine </e2> .\n\n###\n\n", "completion": " true"}
{"id": 219, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2010, "relation": 1, "prompt": "In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.\n\n###\n\n", "completion": " true"}
{"id": 224, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2044, "relation": 1, "prompt": "<e1> Phenothiazines </e1> are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, <e2> opiates </e2> , alcohol, etc.)\n\n###\n\n", "completion": " true"}
{"id": 233, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2165, "relation": 1, "prompt": "<e1> DIFLUCAN </e1> reduces the metabolism of tolbutamide, glyburide, and <e2> glipizide </e2> and increases the plasma concentration of these agents.\n\n###\n\n", "completion": " true"}
{"id": 242, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1> narcotic analgesics </e1> (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2197, "relation": 1, "prompt": "Theophylline: <e1> DIFLUCAN </e1> increases the serum concentrations of <e2> theophylline </e2> .\n\n###\n\n", "completion": " true"}
{"id": 244, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1> meperidine </e1> ), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2218, "relation": 1, "prompt": "Astemizole: The use of <e1> fluconazole </e1> in patients concurrently taking <e2> astemizole </e2> or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.\n\n###\n\n", "completion": " true"}
